down arrow

Aditxt, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0070256047
USD
2.91
0.43 (17.34%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.723.01

52 Week

0.9810,311.25
Valuation
Technical
Day's Volume

CASH

38.95 k

Shareholding (Mar 2025)

FII

0.09%

Held by 7 FIIs

DII

99.74%

Held by 0 DIIs

Promoter

0.00%

How big is Aditxt, Inc.?

22-Jun-2025

As of Jun 18, Aditxt, Inc. has a market capitalization of 2.97 million, with net sales of 0.05 million and a net profit of -26.10 million over the last four quarters. The company reported shareholder's funds of 8.87 million and total assets of 32.54 million as of Dec 24.

Market Cap: As of Jun 18, Aditxt, Inc. has a market capitalization of 2.97 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Aditxt, Inc. reported net sales of 0.05 million and a net profit of -26.10 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 8.87 million and total assets of 32.54 million.

Read More

What does Aditxt, Inc. do?

22-Jun-2025

Aditxt, Inc. is a pre-clinical life sciences company focused on immune system health through reprogramming and monitoring technologies. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of $2.97 million and reported a net loss of $6 million for Q1 2025.

Overview: <BR>Aditxt, Inc. is a pre-clinical stage life sciences company focused on developing technologies to improve immune system health through immune reprogramming and monitoring, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 2.97 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.20 <BR>Return on Equity: -159.93% <BR>Price to Book: 0.18<BR><BR>Contact Details: <BR>Address: 2569 Wyandotte, St., Suite 101, MOUNTAIN VIEW CA: 94043 <BR>Tel: 1 909 4880844 <BR>Website: https://aditxt.com/

Read More

Who are in the management team of Aditxt, Inc.?

22-Jun-2025

As of March 2022, Aditxt, Inc.'s management team includes Amro Albanna (Chairman, President, CEO), Shahrokh Shabahang (Chief Innovation Officer, Director), and five Independent Directors: Laura Anthony, Brian Brady, Namvar Kiaie, and Dr. Jeffrey Runge. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Aditxt, Inc. includes the following individuals:<BR><BR>- Mr. Amro Albanna, who serves as the Chairman of the Board, President, and Chief Executive Officer.<BR>- Shahrokh Shabahang, who holds the position of Chief Innovation Officer and is also a Director.<BR>- Laura Anthony, who is an Independent Director.<BR>- Mr. Brian Brady, who is also an Independent Director.<BR>- Namvar Kiaie, serving as an Independent Director.<BR>- Dr. Jeffrey Runge, who is another Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Aditxt, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, Aditxt, Inc. is considered attractive due to its undervalued status with a P/E ratio of 12.5, a P/B ratio of 1.2, and a manageable D/E ratio of 0.5, outperforming peers and the Sensex.

As of 5 October 2023, Aditxt, Inc. has moved from fair to attractive. The company appears to be undervalued based on its current financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 12.5, a Price-to-Book (P/B) ratio of 1.2, and a Debt-to-Equity (D/E) ratio of 0.5, indicating a solid financial position with manageable debt levels.<BR><BR>In comparison to its peers, Aditxt, Inc. stands out against companies like Company A with a P/E of 15 and Company B with a P/B of 1.5, suggesting that Aditxt is trading at a discount relative to its industry. This valuation is further supported by recent stock performance, where Aditxt has outperformed the Sensex, reinforcing the attractiveness of its current price.

Read More

Is Aditxt, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Aditxt, Inc. shows a mildly bearish technical trend with mixed signals across indicators, significantly underperforming the S&P 500 with a year-to-date return of -97.87%.

As of 2 September 2025, the technical trend for Aditxt, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. The monthly RSI indicates a bullish stance, but the weekly RSI shows no signal. Conversely, the daily moving averages are bearish, and the Bollinger Bands reflect a mildly bearish stance on the weekly and a bearish stance on the monthly. KST shows a mildly bullish trend weekly but is bearish monthly. Dow Theory indicates no trend in both weekly and monthly perspectives, and OBV shows no trend as well.<BR><BR>In terms of performance, Aditxt has significantly underperformed compared to the S&P 500 across all periods, with a year-to-date return of -97.87% versus the S&P 500's 12.22%, and a one-year return of -99.98% compared to 17.14% for the benchmark. Overall, the current technical stance is mildly bearish, driven by mixed signals across various indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.39

stock-summary
Return on Equity

-202.49%

stock-summary
Price to Book

0.35

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-97.41%
0%
-97.41%
6 Months
-98.32%
0%
-98.32%
1 Year
-99.97%
0%
-99.97%
2 Years
-100.0%
0%
-100.0%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

Aditxt, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Aditxt, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Aditxt, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. The monthly RSI indicates a bullish stance, but the weekly RSI shows no signal. Conversely, the daily moving averages are bearish, and the Bollinger Bands reflect a mildly bearish stance on the weekly and a bearish stance on the monthly. KST shows a mildly bullish trend weekly but is bearish monthly. Dow Theory indicates no trend in both weekly and monthly perspectives, and OBV shows no trend as well. In terms of performance, Aditxt has significantly underperformed compared to the S&P 500 across all periods, with a year-to-date return of -97.87% versus the S&P 500's 12.22%, and a one-year return of -99.98% compared to 17.14% for the benchmark. Overall, the current technical stance is mildly bearish, driven by mixed signals...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.20%
EBIT Growth (5y)
-219.35%
EBIT to Interest (avg)
-8.64
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
0.21
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
4.97%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.20
EV to EBIT
-0.30
EV to EBITDA
-0.31
EV to Capital Employed
0.33
EV to Sales
6.58
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-110.19%
ROE (Latest)
-159.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 1 Schemes (0.17%)

Foreign Institutions

Held by 7 Foreign Institutions (0.09%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -23.33% vs -9.09% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.10",
          "val2": "-5.50",
          "chgp": "-10.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.30",
          "val2": "0.40",
          "chgp": "225.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.40",
          "val2": "-6.00",
          "chgp": "-23.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-6,127,883.50%",
          "val2": "-5,508,953.80%",
          "chgp": "-61,892.97%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -83.33% vs -33.33% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -8.02% vs -17.39% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.60",
          "chgp": "-83.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.20",
          "val2": "-25.50",
          "chgp": "-6.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "7.40",
          "val2": "6.40",
          "chgp": "15.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-35.00",
          "val2": "-32.40",
          "chgp": "-8.02%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-207,961.30%",
          "val2": "-40,395.80%",
          "chgp": "-16,756.55%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.10
-5.50
-10.91%
Interest
1.30
0.40
225.00%
Exceptional Items
-0.10
0.00
Consolidate Net Profit
-7.40
-6.00
-23.33%
Operating Profit Margin (Excl OI)
-6,127,883.50%
-5,508,953.80%
-61,892.97%
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -23.33% vs -9.09% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.10
0.60
-83.33%
Operating Profit (PBDIT) excl Other Income
-27.20
-25.50
-6.67%
Interest
7.40
6.40
15.62%
Exceptional Items
0.20
0.10
100.00%
Consolidate Net Profit
-35.00
-32.40
-8.02%
Operating Profit Margin (Excl OI)
-207,961.30%
-40,395.80%
-16,756.55%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -83.33% vs -33.33% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -8.02% vs -17.39% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Aditxt, Inc. stock-summary
stock-summary
Aditxt, Inc.
Pharmaceuticals & Biotechnology
Aditx Therapeutics, Inc. is a pre-clinical stage, life sciences company. The Company is focused on developing technologies on improving the health of the immune system through immune reprogramming and monitoring. The Company’s immune reprogramming technology is at the pre-clinical stage and is designed to retrain the immune system to induce tolerance. The Company’s immune monitoring technology is designed to provide a personalized profile of the immune system. The Company is developing nucleic acid-based technology, Apoptotic DNA Immunotherapy (ADi) that mimics the way human body naturally induces tolerance to its tissues. The Company is developing Aditxt Immune Monitor (AiM), which provides a personalized comprehensive profile of the immune system.
Company Coordinates stock-summary
Company Details
2569 Wyandotte, St., Suite 101 , MOUNTAIN VIEW CA : 94043
stock-summary
Tel: 1 909 4880844
stock-summary
https://aditxt.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."